Abrdn Life Sciences Investors (HQL) return on equity (ROE)

Return on equity · fiscal 2025
16.7%

Abrdn Life Sciences Investors (HQL) earned a return on equity of 16.7% in fiscal 2025 (the year ended September 30, 2025). That is 1.9 percentage points lower than the 18.6% of fiscal 2024. Figures as of 18 Nov 2026, 12:06 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
16.7%
Change on fiscal 2024
−1.9 pts
Highest on record
18.6%fiscal 2024
Lowest on record
-26.3%fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Abrdn Life Sciences Investors return on equity (ROE), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 18.6% in fiscal 2024 and the lowest -26.3% in fiscal 2022. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 5.6%.

History · 4 fiscal years

Return on equity by fiscal year

Abrdn Life Sciences Investors return on equity (ROE), year by year

Abrdn Life Sciences Investors (HQL) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202516.7% 1.9 pts down
202418.6% 13.0 pts up
20235.6% 31.8 pts up
2022-26.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on HQL

Abrdn Life Sciences Investors, figure by figure

Abrdn Life Sciences Investors (HQL) overview: price, valuation and scorecard

Abrdn Life Sciences Investors return on equity (ROE): questions and answers

What is Abrdn Life Sciences Investors's return on equity?

Abrdn Life Sciences Investors (HQL) earned a return on equity of 16.7% in fiscal 2025 (the year ended September 30, 2025). That is 1.9 percentage points lower than the 18.6% of fiscal 2024.

Is Abrdn Life Sciences Investors's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 5.6%.

What are the highest and lowest return on equity figures on record for Abrdn Life Sciences Investors?

Across the 4 fiscal years on record (2022–2025), the highest was 18.6% in fiscal 2024 and the lowest -26.3% in fiscal 2022.

How is Abrdn Life Sciences Investors's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Abrdn Life Sciences Investors it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Abrdn Life Sciences Investors (HQL) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/HQL/roe

Underlying data: Yahoo Finance.